Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Dendreon Slips To Loss, Yet Tops Estimate; Stock Up - Update

Biotechnology company Dendreon Corp. (DNDN: Quote), Monday reported a loss in the fourth quarter from a profit last year, hurt by lower revenues due the absence of royalty income from the sale of hepatitis C drug Victrelis that was included in the year-ago quarter. The quarterly loss was also exacerbated by restructuring and impairment charges.

However, Dendreon's loss was lower when compared with Street estimates, while revenues exceeded expectations. Following the announcement of results, Dendreon stock gained five percent in morning trade on the Nasdaq.

Seattle, Washington-based Dendreon reported fourth-quarter net loss of $38.70 million or $0.26 per share, compared with a net profit of $38 million or $0.26 per share in the prior year quarter.

Results for the reporting quarter included charges of $36 million, relating to restructuring, contract termination and asset impairment.

Excluding items, adjusted loss for the quarter was $45 million or $0.30 per share, compared with a loss of $58 million or $0.40 per share last year.

On average, 21 analysts polled by Thomson Reuters expected a loss of $0.56 per share for the quarter. Analysts' estimates typically exclude special items.

Dendreon, which develops therapeutics to treat cancer, reported quarterly revenues of $85.5 million, compared with $202 million a year ago.

Results for the prior year quarter included Dendreon's 125 million sale of its royalty interest related to intellectual property licensed to Schering-Plough Ltd. and Schering Corp. and associated with Victrelis.

Analysts on consensus estimated revenues of $82.88 million for the quarter.

Research and development costs for the quarter were higher at $19 million, compared with $17.7 million in the prior year.

Dendreon's strategic restructuring has been gaining pace. The company earlier sold its interest in Morris Plains, New Jersey facility to Novartis for $43 million. Dendreon said it expects to reduce cost of goods sold to below 50 percent of net product revenue in the beginning of the third quarter 2013.

The company also anticipates net benefits from restructuring initiatives to begin to appear in financial results as early as the first half of 2013.

Dendreon is trading at $5.94, up $0.27 or 4.76%, on a volume of 6.3 million shares.

Register
To receive FREE breaking news email alerts for Dendreon Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Beverages giant Coca-Cola Co. reported Tuesday a profit for the third quarter that decreased 14 percent from last year, despite higher worldwide volumes, reflecting a revenue drop. Adjusted earnings per share matched analysts' expectations, even as quarterly revenues missed their estimates. Following the announcement, the company's shares are trading more than five percent lower in early deals. Apple Inc. said Monday that its fourth quarter profit rose 13% from last year, driven by strong sales of its iPhones and Mac computers. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly sales. At the same time, the company gave an upbeat revenue forecast for the current quarter, which includes the all important holiday season. Programmable chipmaker Xilinx Inc. (XLNX) said Thursday after the markets closed that its second quarter profit rose 21% from last year, helped by higher revenue and better cost control. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue....
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.